REG - Yourgene Health PLC - Director/PDMR Shareholding

Yourgene HealthAnnouncement

01/08/2019 07:05

RNS Number : 4524H
Yourgene Health PLC
01 August 2019
 


 
Yourgene Health plc
("Yourgene" or the "Company")
 
Director / PDMR Shareholding
 
Manchester, UK - 1 August 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified yesterday that Hayden Jeffreys, Chief Operating Officer and a director of the Company, purchased 83,512 ordinary shares of 0.10p each in the Company yesterday at a price of 11.96 pence per ordinary share.
 
Following the purchase, Hayden Jeffreys holds 305,860 ordinary shares in the Company representing 0.05% of the Company's issued share capital.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
 



For more information, please contact:
 
 








Yourgene Health plc
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
investors@yourgene-health.com
 
 


Tel: +44 (0)161 667 1053
 




Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie / Ludovico Lazzaretti
 
 


Tel: +44 (0)20 7213 0880




Stifel Nicolaus Europe Limited (Broker)
Nicholas Moore / Matthew Blawat / Ben Maddison
 


Tel: +44 (0)20 7710 7600




Walbrook PR Ltd (Media and Investor Relations)
Paul McManus / Lianne Cawthorne / Anna Dunphy
 


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303 / 07876 741 001
 



 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 



Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014




1


Details of the person discharging managerial responsibilities/person closely associated




a.


Name


Hayden Jeffreys




2


Reason for notification


  




a.


Position/Status


Chief Operating Officer




b.


Initial notification/
Amendment


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.


Name


Yourgene Health plc




b.


LEI


213800UUIT8BZE7QEH33




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.


Description of the financial instrument, type of instrument



Identification Code


Ordinary shares of 0.10p each
 
ISIN: GB00BN31ZD89




b.


Nature of the transaction


Purchase of ordinary shares




c.


Price(s) and volume(s)




























Price(s)


Volume(s)








11.96p


83,512














e.


Date of the transaction


31 July 2019




f.


Place of the transaction


London Stock Exchange



 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQFLFXKDFXBBD